Other
David M. Brizel, MD
Total Trials
2
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
Failure Rate
0.0%
0 terminated/withdrawn out of 2 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed trials have results
Key Signals
1 with results
Enrollment Performance
Analytics
Early Phase 1
1(50.0%)
Phase 2
1(50.0%)
2Total
Early Phase 1(1)
Phase 2(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (2)
Showing 2 of 2 trials
NCT00049140Phase 2Completed
EF5 Compared With Other Methods of Detecting Oxygen Levels in Tumor Cells of Patients With Head and Neck Cancer
Role: lead
NCT00140556Early Phase 1Completed
Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer
Role: lead
All 2 trials loaded